Excerpt from Sjogren SyndromeSynonyms, Key Words, and Related Terms: SS, keratoconjunctivitis sicca, KCS, xerostomia, dry mouth, dry eyes, autoimmune disorder, rheumatoid arthritis, systemic lupus erythematosus Please click here to view the full topic text: Sjogren SyndromeBackgroundSjögren syndrome (SS) is an autoimmune disorder characterized by salivary and lacrimal gland dysfunction, resulting in keratoconjunctivitis sicca (KCS) and xerostomia (ie, dry mouth) as a result of immune lymphocytes that infiltrate these secretory glands. Nasal and vaginal mucous membranes are also commonly affected. Other systemic manifestations, most commonly rheumatoid arthritis and systemic lupus erythematosus, can be associated. Although several reports of this condition were documented in the late 1800s, Henrik Sjögren, a Swedish ophthalmologist, described the clinical and pathological findings of this syndrome affecting menopausal women in a classic monograph in 1933. Sjögren syndrome may occur alone (primary) or in conjunction with other autoimmune diseases (secondary). Primary Sjögren syndrome has 2 subsets: patients with systemic immune dysfunction but no defined connective tissue dysfunction, and patients who lack evidence of systemic immune dysfunction or defined connective tissue disease. Secondary Sjögren syndrome occurs in patients who have defined connective tissue disease. The most commonly associated connective tissue diseases are rheumatoid arthritis and systemic lupus erythematosus, but Sjögren syndrome has also been reported in conjunction with progressive systemic sclerosis, Hashimoto thyroiditis, polymyositis, polyarteritis nodosa, and Waldenström macroglobulinemia. PathophysiologyThe pathogenesis of Sjögren syndrome has not been fully elucidated, but the central role of glandular epithelial cells has been identified as key to understanding the disease. An environmental stimulus (eg, viral infection) is believed to trigger inappropriate apoptosis of glandular epithelial cells, producing autoantigens that trigger lymphocytic infiltration of the secretory glands with subsequent production of autoantibodies and cytokines. Dysfunction of residual glandular epithelial cells may also contribute to deficient tear production. Additionally, it has been demonstrated that there is a reduced rate of apoptosis among immune-stimulated lymphocytes, thus exacerbating the loss of glandular secretory function. Sjögren syndrome is also characterized by increased B cell activity. An antigen-driven B cell response has been proposed to occur in the salivary glands of patients with Sjögren syndrome. Patients with Sjögren syndrome are at an increased risk of developing B cell non-Hodgkin lymphoma and other lymphoproliferative disorders. In fact, 5% of patients with primary Sjögren syndrome develop B cell non-Hodgkin lymphoma. This increased risk has been attributed to B cell hyperactivity and reduced natural killer cell activity. FrequencyUnited StatesThe incidence has been estimated by the San Diego criteria as 0.5%. InternationalThe European study group estimates an incidence of 3-5%. Mortality/MorbiditySevere dry eyes can cause corneal scarring, ulceration, infection, and even perforation. SexThe female-to-male ratio is 9:1. AgeAlthough primarily a disease of postmenopausal women, age can range from 22-70 years, with the average age being 43 years. There is often a delay of 5-10 years between disease onset and diagnosis. Sjögren syndrome has also been reported in children who developed recurrent parotid gland enlargement. Please click here to view the full topic text: Sjogren Syndrome |
| About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers |
|
|
|||
|
| Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |